1	Mutations on non-structural proteins of SARS-CoV-2 are possibly responsible for
2	adverse clinical outcomes in a real-life practice
3	
4	Takaya Ichikawa ¹ , Shiho Torii ² , Hikoyu Suzuki ³ , Akio Takada ⁴ , Satoshi Suzuki ¹ , Masahide
5	Nakajima ⁵ , Akihito Tampo ⁶ , Yasutaka Kakinoki ¹
6	1. Division of Internal Medicine, Asahikawa City Hospital, Asahikawa, Japan
7	2. Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University,
8	Suita, Japan
9	3. digzyme Inc., Tokyo, Japan
10	4. Department of Pathology, Asahikawa City Hospital, Asahikawa, Japan
11	5. Department of Pediatrics, Asahikawa City Hospital, Asahikawa, Japan
12	6. Department of Emergency Medicine, Asahikawa City Hospital, Asahikawa, Japan
13	
14	Corresponding author
15	Takaya Ichikawa, D.V.M., M.D.
16	Asahikawa City Hospital, 1-1-65, Kinsei-cho, Asahikawa, Hokkaido, Japan
17 18	e-mail: ichikawa.honest2.go@gmail.com
19	Keywords: COVID-19, SARS-CoV-2, non-structural protein, mutation, clinical outcome

20

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 Abstract

22Among a single COVID-19 cluster population from the end of March through April 2021 in 23Asahikawa, we experienced the cases in which patients manifested severe clinical symptoms 24compared to patients who were infected before that. A hundred three patients (age range: 65 to 89 25years old) enrolled in this study were divided into two groups, group A: the patients infected from 26November 2020 to March 2021, and group B: the patients in this cluster population. The mortality 27rates were 6.1% in group A and 16.2% in group B (OR: 2.97, 95%CI: 0.65-15.38). For the severity of 28disease, the patients in group B reached to the clinical state which requires higher oxygen flow rate 29more quickly (mild; p=0.892, moderate; p=0.117, severe; p=0.029). Whole viral genome sequences 30 revealed five non-synonymous mutations by comparison of the isolates with each group. Of these, 31four were on NSPs including nsp3, 6 and 15, and one was on S protein located near the C-terminus, 32suggesting that mutations on NSPs could be responsible for adverse clinical outcomes in COVID-19 33 patients.

34

35 Introduction

36The Coronavirus disease 2019 (COVID-19), which is caused by Severe acute respiratory syndrome 37coronavirus 2 (SARS-CoV-2), initially broke out in Wuhan, China, on December 2019 and has 38subsequently spread around the world [1]. SARS-CoV-2 is an enveloped virus with a positive-sense 39 single-stranded RNA genome of approximately 30 kb. Two-thirds of the viral genome at the 5' 40terminus contains ORF1a and ORF1b, which encodes 16 non-structural proteins (NSPs). These NSPs 41 play crucial roles in viral replication and evasion of host immune systems [2]. The other one-third of the 3' end contains structural genes such as spike glycoprotein (S protein), envelope protein, membrane 4243protein, nucleocapsid protein, and several accessory proteins [3]. Because replication of RNA viruses 44typically has a low fidelity, the viral genome of SARS-CoV-2 has accumulated mutations at an average 45of two nucleotides per month [4]. On 25th February 2021, World Health Organization (WHO) defined

48be associated with increase in transmissibility virulence to or 49(https://www.who.int/emergencies/diseases/novel-coronavirus-2019). For example, VOC-202012/01 50(pango lineage B.1.1.7), as it is called "alpha variant", has higher transmissibility and mortality 51compared to a reference isolate [5,6]. These variants, however, were not focused on mutations in NSPs, 52but in structural proteins, especially S protein. It remains unclear whether mutations in NSPs are 53responsible for the virulence of COVID-19.

54As of October 2021, COVID-19 is responsible for 1.7 million cases and 18 thousand deaths 55in Japan (https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou.html). The most remarkable 56clinical feature of this disease is its heterogeneity in clinical manifestations, ranging from no symptoms 57to critical illness [7]. Several risk factors for symptom severity have been known, such as age (over 5865 years old), male sex, obesity, history of smoking, and comorbidities (including hypertension, 59diabetes mellitus, respiratory disease, cardiovascular disease, chronic kidney disease and cancer) 60 [8,9,10,11]. In Japan, the several treatment options are currently recommended based on the symptom 61severity: Casirivimab and Imdevimab, remdesivir, dexamethasone and baricitinib 62(https://www.mhlw.go.jp/content/000815065.pdf). In clinical practice, methylprednisolone is also 63 used for critically ill patients when they have a poor response for the dexamethasone therapy or when 64 baricitinib is not available [12].

65In Asahikawa city, Hokkaido prefecture located in northern part of Japan, the cluster of 66 COVID-19 cases occurred in several bars where a group of customers enjoyed "karaoke" during 67 daytime from the end of March through April 2021 (referred to bellow as cluster K), and 66 cases were 68 involved into the infection according city's to the survey 69 (https://www.city.asahikawa.hokkaido.jp/kurashi/135/136/150/index.html). We found that the 70progression of disease among the patients in this particular cluster were faster compared to patients

71 who were infected before that. Therefore, in order to identify factors associating the progression of 72 disease, we examined the viral genome sequences along with the clinical characteristics and treatment 73 strategies, and then compared those with other cases.

74

75 Material and Method

76 *Participants*

77All adult patients with COVID-19 who were admitted to Asahikawa City Hospital from November 782020 to April 2021 were enrolled in this retrospective study. All positive results were confirmed by 79 real-time RT-PCR for the presence of SARS-CoV-2 in saliva or nasopharyngeal swab samples. The 80 recovered patients were discharged from the hospital following the discharge criteria provided by 81 Japanese Ministry of Health, Labour and Welfare when two criteria have met: 10 days passed from the 82symptom onset and 72 hours passed from the symptom resolution, or when two consecutive negative 83 PCR results are confirmed. Opt-out consent was obtained instead of written informed consent. We 84 provided the patients with information explaining the proposed research plan via the website of 85 Asahikawa City Hospital, and with the opportunity to opt out.

86

87 Clinical data collection and definitions

The epidemiological data, medical history, underlying comorbidities, symptoms and signs at admission, oxygen flow rate, treatment and clinical outcomes were obtained from electronic medical records. Because the date of onset was unclear for some patients who were asymptomatic, we considered the date on which positive PCR result was obtained as day 0. Clinical outcomes were followed up until discharge or death. The primary outcome was mortality rate, and the secondary outcome was oxygen flow rate as a severity of the disease; mild: ≥ 1 L/min, moderate: ≥ 5 L/min and severe: ≥ 10 L/min.

95

96 Viral genome sequence

97 The stored RNA extracts were used as clinical samples. Fist-strand cDNA was synthesized by using a 98 PrimeScript IV 1st strand cDNA Synthesis Mix (TaKaRa Bio) with random hexamer primers and 99extracted RNA, according to the manufacture's protocols. The whole-genome sequencing of SARS-100 CoV-2 was carried out as reported previously [13]. Briefly, a total of 10 gene fragments were amplified 101 with synthesized cDNA, specific primer sets for SARS-CoV-2 and PrimeSTAR GXL DNA 102polymerase (TaKaRa Bio). Then, the amplified products were directly sequenced in both directions by 103 using the ABI PRISM 3130 Genetic Analyzer (Applied Biosystems) with specific primers. Our raw 104 sequence data were converted to FASTQ format by in-house Python script with BioPython module 105[14], followed by trimming first 50 bps and the region after 900 bps by FASTX-Toolkit 106 (http://hannonlab.cshl.edu/fastx_toolkit/). Trimmed sequence reads were mapped to the SARS-CoV-2 107reference genome (accession number MN908947.3).

108

109 Phylogenetic analysis

More than 1 million SARS-CoV-2 published genome sequences whose length were between 29,000 -30,000 bps were downloaded from National Center for Biotechnology Information (NCBI) via Application Programming Interface (API) for the Entrez Programming Utilities (E-utilities) (https://www.ncbi.nlm.nih.gov/books/NBK25497/). Sequences including less than 29,000 definite bases, neither 'N' nor other mixed bases, were discarded.

All SARS-CoV-2 genome sequence data, including our assemblies, were mapped to the reference genome (accession number MN908947.3). Based on the SAM format mapping output, SNPs and short INDELs were detected and categorized to synonymous, non-synonymous or intergenic mutations by in-house Perl scripts, which simply picked up the differences from the reference sequence for each genome. For the phylogenetic analysis, a typical genome sequence of each variant, named alpha, beta, gamma, delta, epsilon, zeta, eta, theta, iota, kappa, and lambda by WHO, were

121chosen from the published data based on the following criteria; neither 'N 'nor other mixed bases 122were included in open reading frames (ORFs), number of substitution sites in ORFs were less than 123100, all non-synonymous mutations which characterize each variant were included, and all other 124substitutes observed in more than 95% of the samples that satisfy the above conditions were also 125included. The non-synonymous mutations which characterize each variant are shown in Table S1, 126created based on the mutation prevalence information from outbreak.info (https://outbreak.info/). 127ORF10 was excluded from the analyses because one of our assemblies did not completely cover that 128region. Based on the alignment, suitable nucleotide substitution models for each partition were 129selected by ModelTest-NG [15], followed by maximum likelihood phylogenetic analyses using the 130 selected substitution models by RAxML-NG [16]. The constructed phylogenetic tree was drawn and 131edited by MEGA X [17].

132

133Statistical analysis

134We performed group comparisons using Fisher's exact test for categorical variables, and independent 135group t-test for continuous variables. The categorical variables were expressed as frequencies 136(percentage), and the continuous variables as the median with interquartile range. Odds ratios (OR) 137with 95% confidence interval were calculated for the rates of mortality and the required oxygen flow 138rate. Cumulative probabilities of oxygen therapy were described with using the Kaplan-Meier analysis 139and compared using log-rank test. P-values of 0.05 or less were considered statistically significant. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, 140141 Saitama, Japan, version 1.54) [18], which is a graphical user interface for R software (The R 142Foundation for Statistical Computing, Vienna, Austria).

143

144Result

A total of 191 patients diagnosed with COVID-19 were admitted to our hospital from November 2020 145

146to April 2021. The patients were divided into two groups, group A: the patients infected from 147November 2020 to March 2021, and group B: the patients whose infection was traced from the cluster 148K. We included the patients whose ages range between 65 and 89 years old for the following reasons; 1491) patients who are younger than 65 years old are not necessarily requested for hospitalization in our 150health care system, 2) in group A, many patients over 90 years old were transferred from a 151convalescent hospital where COVID-19 outbreak had occurred, thus the age profiles would be much different from group B if the patients aged over 90 years old were included in this group. Finally, 66 152153patients were assigned to group A and 37 patients to group B (Figure 1).

154The clinical characteristics and treatment strategies used during hospitalization are shown 155in Table 1. Although there were no significant differences in clinical characteristics between the two 156groups, obesity and lifestyle-related diseases such as hypertension, dyslipidemia and diabetes tended 157to be more prevalent in group B. In treatment strategies, remdesivir tended to be used more frequently 158in group A and methylprednisolone in group B.

Four patients of 66 patients (6.1%) in group A and six of 37 patients (16.2%) in group B 159160 died from COVID-19 (OR: 2.97, 95%CI: 0.65-15.38) (Table 2). When limited to males, the differences 161 in number of deaths became larger (6.3% vs 29.4%, OR: 5.99, 95%CI: 0.84-71.2). The clinical 162characteristics and the treatment of 10 deceased patients are shown in Table S2. Cumulative probability of the patients who required minimal oxygen therapy (mild) were similar in both groups 163164(Table 2, Figure 2A). However, the patients in group B were likely to require more oxygen therapy in 165earlier course of hospitalization (Figure 2B, 2C). There was no significant difference in the cumulative 166 probability between group A and B for moderate oxygen therapy (p=0.117), but for the severe oxygen 167therapy, the significant difference was observed (p=0.029). As with mortality, males in group B 168showed worse outcomes when required severe oxygen therapy (Table 2).

169 Assuming that these differences in clinical outcomes would be due to viral factors, we 170examined the whole viral genome sequences representing two samples in each group, named

171Asahikawa 0108 and Asahikawa 0122 isolated in January 2021 and Asahikawa 0404 and 172Asahikawa 0417 isolated in April 2021. The mutation sites which differed in these four samples are 173summarized in Table 3. Focusing on the non-synonymous mutations, five amino acid changes were 174identified (represented in bold). Of these, four amino acid changes were located on NSPs and one was 175on S protein, as illustrated in the viral genome scheme of SARS-CoV-2 (Figure 3). In order to assess 176strain relatedness, the phylogenetic analysis was carried out. The isolates in this study were closely 177related to the strain previously isolated in Japan (accession number BS000756.1; pango lineage 178B.1.1.214), but not to any of the variants labeled by WHO (Figure 4).

179

180 **Discussion**

We hereby reported the single COVID-19 cluster population (cluster K) case in which the conventional treatment was unsuccessful and the hospitalized patients became more severely ill, thus performed the retrospective analysis to find out the causative factors. The patients in group B had a higher mortality rate compared to group A, but no significant difference was indicated. For the severity of disease, the patients in group B required higher oxygen flow rate in early course of admission. Furthermore, the differences became larger when limited to males, with 41.2% of male severe patients in group B against 6.3% in group A.

188 In terms of treatment strategies, we were likely to use methylprednisolone monotherapy for 189severe cases in group B. This was because we had experienced that, in the winter of 2020, patients 190who received methylprednisolone therapy appeared to have a better response than those who were 191treated with remdesivir after poor response for dexamethasone, although the treatment guideline for 192COVID-19 in Japan recommends the use of remdesivir for patients with pneumonia whose oxygen 193saturation falls below 96% (https://www.mhlw.go.jp/content/000815065.pdf). In our study, there was 194 no significant difference of remdesivir usage between two groups, therefore the viral factors could 195have an impact on the clinical outcomes.

196 Whole viral genome sequences revealed five non-synonymous mutations by comparison of 197 the isolates with each group. Interestingly, four of them were on NSPs. The sole structural mutation, 198D1153G on S protein, was located near the C-terminus and outside the range of three-dimensional 199structures obtained by crystallography, suggesting neither the head nor stalk of S protein. Therefore, 200D1153G is not expected to involve in the virulence of the disease. Of the four mutation sites on NSPs, 201two were found on nsp6 (T3598I and Y3722C), and the rest of them were on nsp3 (E2089D) and 202nsp15 (A2143S). To our knowledge, none of these mutations are known to be the factors that determine 203the severity of disease in clinical practice, and it is unclear whether the mutations affect the function 204of these NSPs. However, all of them have been reported to play roles in suppression of type 1 interferon 205in host cells [19,20,21], and also nps6 involves in the formation of autophagosome in host cells [22]. 206The potential sites under positive selective pressure have been found on nsp6 near T3598I according 207to an evolutionary analysis on SARS-CoV-2 genome sequences of 351 clinical samples [23]. Therefore, 208the mutations on nsp3, 6 and 15 could be responsible for its function to interact with host immunity 209 and autophagy. Further investigations are required to reveal their functions and involvement in the 210virulence.

211The phylogenetic analysis revealed that the isolates in this study are derived from pango lineage B.1.1.214 which was the dominant strain in so-called "the third wave", the epidemic period 212213from October to December 2020 in Japan [24]. Considering the fact that any strains identical to the 214viral sequence of group B cannot be found in more than 1,000,000 registered sequences in NCBI, it is likely that the virus evolved locally from January to April 2021 in Hokkaido. Since May 2021, alpha 215216variant has been dominant throughout Japan including Hokkaido; 78% of the samples isolated from 217April 26 May 2 2021 in Hokkaido already alpha variant to were 218(https://www.mhlw.go.jp/content/10900000/000779013.pdf). As a consequence, B.1.1.214 strains in 219Asahikawa seems to be eliminated. This is similar to the situation in influenza A virus, for example, where pandemic influenza A (H1N1) pdm09 replaced Russian flu (H1N1) since 2009 [25,26]. 220

221	There are some limitations to this retrospective study. First, the recommended therapy for
222	COVID-19 have been changing dynamically. Because the best treatment strategies are selected based
223	on the evidence at that time, it is difficult to compare clinical outcomes between different periods of
224	time in real-life practice. Second, this is a single institution study; not all cases in cluster K have been
225	assessed. The mortality and severity rate would be different when including cases admitted to other
226	hospitals. Third, we examined only two samples from each group in this study. Due to the limited
227	human and financial resources, we were unbale to perform the viral genome analysis of much more
228	samples.
229	In conclusion, the present study demonstrated that some viral factors, four non-synonymous
230	mutations on nsp3, 6 and 15 but not on S protein, could be responsible for adverse clinical outcomes
231	in COVID-19 patients. Though scientists and physicians all over the world have focused on the S
232	protein mutations, in order to comprehensively understand the epidemiology of COVID-19, we should
233	have an insight into other type of mutations such as those on NSPs.
234	
235	Acknowledgment
236	We thank Prof. Yoshiharu Matsuura, Osaka University, for funding the viral sequence analysis. We
237	also thank our medical team worked on COVID-19 and all of the staff at Asahikawa Health Center for
238	their support.
239	
240	Declaration of interests
241	Authors have no conflicts of interests.
242	
243	Reference
244	1. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species
245	
	Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it

246 SARS-CoV-2. Nat Microbiol. 2020;5: 536–544. doi:10.1038/s41564-020-0695-z

- 247 2. Maier HJ, Bickerton E, Britton P. Coronaviruses: Methods and protocols. Coronaviruses Methods
- 248 Protoc. 2015;1282: 1–282. doi:10.1007/978-1-4939-2438-7
- 249 3. Hagemeijer MC, Verheije MH, Ulasli M, Shaltiël IA, de Vries LA, Reggiori F, et al. Dynamics of
- 250 Coronavirus Replication-Transcription Complexes. J Virol. 2010;84: 2134–2149.
 251 doi:10.1128/jvi.01716-09
- 4. Duchene S, Featherstone L, Haritopoulou-Sinanidou M, Rambaut A, Lemey P, Baele G. Temporal
- signal and the phylodynamic threshold of SARS-CoV-2. Virus Evol. 2020;6: 1–8.
 doi:10.1093/ve/veaa061
- 255 5. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated
- transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (80-). 2021;372.
 doi:10.1126/science.abg3055
- Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of
 mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched cohort
 study. BMJ. 2021;372: 1–10. doi:10.1136/bmj.n579
- 261 7. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline
- 262 Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of
- 263 the Lombardy Region, Italy. JAMA J Am Med Assoc. 2020;323: 1574–1581.
- 264 doi:10.1001/jama.2020.5394
- 8. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Since January 2020 Elsevier has created a COVID-
- 266 19 resource centre with free information in English and Mandarin on the novel coronavirus
- 267 COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company 's
 268 public news and information . 2020.
- Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity
 and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev.

- 271 2020;21: 1–17. doi:10.1111/obr.13128
- 272 10. Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol.
- 273 2020;16: 705–706. doi:10.1038/s41581-020-00349-4
- 11. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection:
- a nationwide analysis in China. Lancet Oncol. 2020;21: 335–337. doi:10.1016/S14702045(20)30096-6
- 277 12. Pinzón MA, Ortiz S, Holguín H, Betancur JF, Arango DC, Laniado H, et al. Dexamethasone vs
- 278 methylprednisolone high dose for Covid-19 pneumonia. PLoS One. 2021;16: 1-13.
- doi:10.1371/journal.pone.0252057
- 280 13. Torii S, Ono C, Suzuki R, Morioka Y, Anzai I, Fauzyah Y, et al. Establishment of a reverse genetics
- system for SARS-CoV-2 using circular polymerase extension reaction. Cell Rep. 2021;35: 109014.
 doi:10.1016/j.celrep.2021.109014
- 283 14. Cock PJA, Antao T, Chang JT, Chapman BA, Cox CJ, Dalke A, et al. Biopython: Freely available
- 284 Python tools for computational molecular biology and bioinformatics. Bioinformatics. 2009;25:
- 285 1422–1423. doi:10.1093/bioinformatics/btp163
- 286 15. Darriba Di, Posada D, Kozlov AM, Stamatakis A, Morel B, Flouri T. ModelTest-NG: A New and
- 287 Scalable Tool for the Selection of DNA and Protein Evolutionary Models. Mol Biol Evol. 2020;37:
- 288 291–294. doi:10.1093/molbev/msz189
- 289 16. Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A. RAxML-NG: A fast, scalable and user-
- friendly tool for maximum likelihood phylogenetic inference. Bioinformatics. 2019;35: 4453-
- 291 4455. doi:10.1093/bioinformatics/btz305
- 292 17. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular evolutionary genetics
- analysis across computing platforms. Mol Biol Evol. 2018;35: 1547–1549.
 doi:10.1093/molbev/msy096
- 295 18. Kanda Y. Investigation of the freely available easy-to-use software "EZR" for medical statistics.

296 Bone Marrow Transplant. 2013;48: 452–458. doi:10.1038/bmt.2012.244

- 297 19. Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Papain-like protease
- regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587: 657–662.
- 299 doi:10.1038/s41586-020-2601-5
- 20. Xia H, Cao Z, Xie X, Zhang X, Chen JYC, Wang H, et al. Evasion of Type I Interferon
- 301 by SARS-CoV-2. Cell Rep. 2020;33: 108234. doi:10.1016/j.celrep.2020.108234
- 302 21. Yuen C-K, Lam J-Y, Wong W-M, Mak L-F, Wang X, Chu H, et al. SARS-CoV-2 nsp13, nsp14,
- 303 nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect. 2020;9: 1418–
- 304 1428. doi:10.1080/22221751.2020.1780953
- 22. Cottam EM, Whelband MC, Wileman T. Coronavirus NSP6 restricts autophagosome
 expansion. Autophagy. 2014;10: 1426–1441. doi:10.4161/auto.29309
- 307 23. Benvenuto D, Angeletti S, Giovanetti M, Bianchi M, Pascarella S, Cauda R, et al.
- 308 Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6
- 309 (NSP6) could affect viral autophagy. J Infect. 2020;81: e24-e27.
- 310 doi:10.1016/j.jinf.2020.03.058
- 311 24. National Institute of Infectious Diseases, Infectious Agents Surveillance Report. 2021;42: 61-64.
- 312 25. Blyth CC, Kelso A, McPhie KA, Ratnamohan VM, Catton M, Druce JD, et al. The impact of the
- 313 pandemic influenza a(H1N1) 2009 virus on seasonal influenza a viruses in the southern
- 314 hemisphere, 2009. Eurosurveillance. 2010;15: 1–5. doi:10.2807/ese.15.31.19631-en
- 26. Broor S, Krishnan A, Roy DS, Dhakad S, Kaushik S, Mir MA, et al. Dynamic patterns of
- 316 circulating seasonal and pandemic A(H1N1)pdm09 influenza viruses from 2007-2010 in and
- 317 around Delhi, India. PLoS One. 2012;7: 1–9. doi:10.1371/journal.pone.0029129

318

Characteriatia	Group A Group B		Dyelue	
Charactenstic	(N=66)	(N=37)	P value	
Age, median (IQR)	76 (71-85)	78 (74-82)	0.75	
Male sex (%)	32 (48.5)	17 (45.9)	0.84	
Duration of hospitalization,	12 5 (0, 16)	11 (50 16)	0.85	
median (IQR)	12.5 (9-16)	11 (59-16)		
Obesity, BMI ≥30 (%)	4 (6.1)	6 (16.2)	0.16	
Current or ex-smoker (%)	21 (31.8)	13 (35.1)	0.83	
Comorbidities (%)				
Hypertention	38 (57.6)	28 (75.7)	0.09	
Dyslipidemia	21 (31.8)	16 (43.2)	0.29	
Diabetes mellitus	12 (18.2)	10 (27.0)	0.32	
Chronic pulmonary disease	12 (18.2)	11 (29.7)	0.22	
Cardiovascular disease	10 (15.2)	7 (18.9)	0.78	
Chronic kidney disease	10 (15.2)	6 (16.2)	1.00	
Cancer	9 (13.6)	2 (5.4)	0.32	
Treatment options (%)				
Dexamethasone	39 (59.1)	19 (51.4)	0.54	
Methylprednisolone	10 (15.2)	11 (29.7)	0.12	
Remdesivir	8 (12.1)	2 (5.4)	0.32	

Table 1. Characteristics and treatment options of COVID-19 patients

IQR: interquartile range, BMI: body mass index

319

•	v	-					
	Over all			Male			
0.4	Group A	Group B		Group A	Group B		
Outcome	(N=66)	(N=37)	OR (95%CI)	(N=32)	(N=17)	UR (95%CI)	
Death (%)	4 (6.1)	6 (16.2)	2.97 (0.65-15.38)	2 (6.3)	5 (29.4)	5.99 (0.84-71.2)	
Severity [*] (%)							
Mild	27 (40.9)	15 (40.5)	0.98 (0.40-2.41)	15 (46.9)	9 (52.9)	1.27 (0.34-4.89)	
Moderate	9 (13.6)	9 (24.3)	2.02 (0.63-6.47)	4 (12.5)	8 (47.1)	5.95 (1.25-33.9)	
Severe	5 (7.6)	8 (21.6)	3.32 (0.87-14.11)	2 (6.3)	7 (41.2)	6.68 (1.24-47.8)	

320 Table 2. Primary and secondary outcomes of COVID-19 patients

* Oxygen flow rate: Mild ≥1 L/min, Moderate ≥5 L/min, Severe ≥10 L/min

Nucleotide	0	Group A		Gro	Amino acid	
position	Gene	Asahikawa_0108	Asahikawa_0122	Asahikawa_0404	Asahikawa_0417	change
4233		G	А	А	А	D1323G
6380		С	т	С	С	L2039F
6433		т	С	С	С	Syn
6532		G	G	т	т	E2089D
6997		Т	С	С	С	Syn
8371		т	G	G	G	Q2702H
8917	Orf1a	С	т	т	т	Syn
9207		т	С	С	С	S2981F
10042		А	А	G	G	Syn
11058		С	С	т	т	T3598I
11430		А	А	G	G	T3722C
12049		С	Т	т	т	Syn
13366		С	С	т	т	Syn
15240		Т	С	С	С	Syn
15957		G	А	G	G	Syn
17502	Orf1b	С	т	С	С	Syn
19894		G	G	Т	Т	A2143S
20658		А	G	А	А	Syn
22502		С	А	С	С	Q314K
23191		С	С	Т	Т	Syn
23587	c	G	Т	Т	т	Q675H
23720	3	G	А	А	А	I720V
24748		С	С	Т	Т	Syn
25020		А	А	G	G	D1153G
29353	Ν	С	Т	Т	Т	Syn

Table 3. Mutation sites that differed in the four samples

Position number based on alignment to NCBI reference sequence: NC_045512 (Wuhan-Hu-1). The different parts between the two samples in group A are shown in a gray area. Amino acid changes identified between two groups were represented in bold.

321

322

323 Figure Legends

324

325	Figure 1.	. Flow diagram	indicating the	e recruitment	process in	this study.
		· · · · · · · · · · · · · · · · · · ·			p1000000 mi	and been j.

326

327 Figure 2. Cumulative probability of the patients who required oxygen therapy with mild: $\geq 1 \text{ L/min}$,

328 moderate: \geq 5 L/min and severe: \geq 10 L/min. The log-rank test was used for statistical analysis.

329

330 Figure 3. Scheme of SARS-CoV-2 genome. The non-synonymous mutation sites are indicated by

arrows.

332

333 Figure 4. Maximum likelihood phylogenetic tree of SARS-CoV-2 variants. Black and rend characters

indicate synonymous and non-synonymous mutations respectively. Red bold characters indicate

335 mutations of interest. Numbers on internal nodes are bootstrap values for each divergence.







